Three-year follow-up of carcinoembryonal antigen levels in the serum of patients with breast cancer.
The levels of carcinoembryonal antigen (CEA) were followed up for three years in 66 patients with breast cancer. In the group of patients treated surgically (N = 36, T1-2, NO-2, MO) the values of CEA were in agreement with the clinical course in 97% of the patients (35 out of 36 patients). Recurrence and/or dissemination of the disease were signalled by a rise in the serum CEA level to more than 15 micrograms/1 out four out of five patients more than 3-10 months before clinical manifestation. In the group of patients without surgery, who were treated by radiation and/or chemotherapy (N = 30, T2-4, NO-3, MO) the serum CEA values were in agreement with the clinical course in 71% of the patients (20/28). Within three years recurrence and/or dissemination were detected in 57% patients (16/28), ten patients died (10/30--two of them were not evaluated). The recurrence or dissemination were signalled in seven out of 16 patients (44%) more than 4-14 months before clinical detection, in three patients (19%) the rise was detected simultaneously with the clinical finding (examinations at 3-4 months intervals), and in 6 patients (38%) the CEA level was at variance with the clinical finding.
D001943:Breast Neoplasms / Q000276:immunology* / Q000401:mortality / Q000628:therapy; D002272:Carcinoembryonic Antigen / Q000032:analysis*; D003131:Combined Modality Therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D013997:Time Factors
D002272:Carcinoembryonic Antigen